Current Report Filing (8-k)
May 12 2022 - 04:11PM
Edgar (US Regulatory)
0000811240false00008112402022-05-122022-05-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
Date of Report (Date of earliest event reported):
May 12, 2022
|
BIOLASE, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
001-36385
|
87-0442441
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
27042 Towne Centre Drive,
Suite 270
|
|
Lake Forest,
California
|
|
92610
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area
Code: (949)
361-1200
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
BIOL
|
|
The NASDAQ Stock Market LLC
(NASDAQ Capital Market)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On May 12, 2022, BIOLASE, Inc. issued a press release announcing
its financial results for the first quarter ended March 31, 2022. A
copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is hereby incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
The following exhibit is being furnished as part of this Current
Report on Form 8-K:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
BIOLASE, INC.
|
|
|
|
|
|
Date: May 12, 2022
|
|
By
|
|
/s/ John R. Beaver
|
|
|
|
|
Name: John R. Beaver
|
|
|
|
|
Title: President and Chief Executive Officer
|
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jun 2022 to Jul 2022
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jul 2021 to Jul 2022